Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) Director Daniel Swisher, Jr. sold 1,500 shares of the stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $74.07, for a total transaction of $111,105.00. Following the completion of the sale, the director directly owned 1,100 shares in the company, valued at $81,477. This trade represents a 57.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Corcept Therapeutics Price Performance
Shares of NASDAQ:CORT opened at $72.94 on Monday. The business has a 50 day simple moving average of $103.70 and a two-hundred day simple moving average of $76.43. Corcept Therapeutics Incorporated has a 1 year low of $28.66 and a 1 year high of $126.38. The firm has a market capitalization of $7.98 billion, a PE ratio of 57.43 and a beta of 0.54.
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The biotechnology company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.84 by $0.17. The company had revenue of $340.47 million for the quarter, compared to the consensus estimate of $339.12 million. Corcept Therapeutics had a return on equity of 22.56% and a net margin of 16.53%. Corcept Therapeutics’s quarterly revenue was up 64.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.16 EPS. Equities research analysts expect that Corcept Therapeutics Incorporated will post 1.97 EPS for the current fiscal year.
Analysts Set New Price Targets
Several analysts recently weighed in on the company. Weiss Ratings upgraded Corcept Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, November 4th. Wolfe Research lowered Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price for the company. in a report on Monday, July 27th. Truist Financial assumed coverage on Corcept Therapeutics in a research report on Tuesday, August 18th. They issued a “buy” rating and a $164.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $165.00 target price on shares of Corcept Therapeutics in a research report on Friday, September 18th. Finally, Piper Sandler reissued an “overweight” rating and issued a $173.00 price target (up from $165.00) on shares of Corcept Therapeutics in a report on Wednesday, November 4th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $139.50.
Get Our Latest Report on Corcept Therapeutics
Institutional Investors Weigh In On Corcept Therapeutics
Several hedge funds have recently added to or reduced their stakes in the business. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Corcept Therapeutics in the 2nd quarter valued at about $27,000. State of Wyoming lifted its stake in shares of Corcept Therapeutics by 29.5% in the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 186 shares during the period. Provenance Wealth Advisors LLC purchased a new stake in Corcept Therapeutics during the third quarter worth $38,000. Gould Capital LLC boosted its holdings in Corcept Therapeutics by 66.7% during the first quarter. Gould Capital LLC now owns 1,000 shares of the biotechnology company’s stock worth $40,000 after buying an additional 400 shares in the last quarter. Finally, Fulcrum Asset Management LLP grew its position in Corcept Therapeutics by 520.7% during the third quarter. Fulcrum Asset Management LLP now owns 571 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 479 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.
Corcept Therapeutics Company Profile
Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body’s response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.
Featured Articles
- Five stocks we like better than Corcept Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
